Article Sidebar
Published:
Dec 27, 2024DOI:
10.4314/rjmhs.v7i3.8Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
During the submission, authors will be requested to complete a ‘Copyright Transfer form' to assign to the University of Rwanda the copyright of the manuscript and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed), throughout the world, in all languages, for the full term of copyright, effective when the article is accepted for publication. The Creative Commons Attribution NonCommercial-NoDerivs (CC-BY-NC-ND) license shall be applied.
Main Article Content
Assessment of Dyslipidaemia and Cardiovascular Disease Risk Factors among Type 2 Diabetes Mellitus Patients Attending Kabutare District Hospital, Huye, Rwanda
Abstract
Background
Dyslipidaemia is a major contributing factor to the development of cardiovascular disease (CVD) in type 2 diabetic mellitus (T2DM) patients. People with T2DM are at a significantly high risk of developing dyslipidaemia which in turn is a risk factor for CVD. The objective of this study was to assess the risk factors for CVD in T2DM patients.
Methodology
A descriptive cross-sectional study was conducted on 100 T2DM patients consecutively presenting at Kabutare District Hospital, Huye District southern Rwanda. Excluded were patients on lipid lowering drugs and those with chronic renal and liver diseases.
Results
The overall prevalence of dyslipidaemia was 79% with hypoalphalipoproteinaemia (47%) being the most common and hypercholesterolaemia (29%) the least frequent. When stratified according to glycaemic control, median diastolic blood pressure was significantly higher (p=0.045) in participants whose median fasting plasma glucose (FPG) was ≥5.6 mmol/L. Median fasting triglycerides (p=0.006) and non-HDL-C (p=0.019) concentrations were significantly lower in euglycaemic participants compared to participants with median FPG ≥5.6 mmol/L. Dysglycaemia was significantly associated with dyslipidaemia status (p=0.001).
Conclusion
Effective management and monitoring of dyslipidaemia, particularly among those with poor glycaemic control, is crucial in mitigating CVD risks in this population.
Rwanda J Med Health Sci 2024;7(3):471-484
